Analyst Profile

Followed by 95 followers
.
Ami Fadia

Ami Fadia

Needham
Wall Street Analyst
#2,349 out of 8,160 Wall Street Analysts
#5,107 out of 24,427 experts

Success Rate

51%
98 out of 192 transactions made a profit

Average Return

+3.70%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
Copying Ami Fadia's trades since 2012 and holding each position for 1 Year would result in 51.04% of your transactions generating a profit, with an average return of 3.7% per rating.

Stock Rating Distribution

345Ratings
70.14% Buy
28.41% Hold
1.45% Sell
Distribution of Ami Fadia's ratings

Additional Information

Main Sector:Healthcare
Geo Coverage:
United StatesUS Market

Best Rating

Stock:
Avadel Pharmaceuticals
(AVDL)
Rating:Buy
Date:May 27, 2022 - Today
Return:+266.80%
The most profitable rating made by Ami Fadia

Ami Fadia's Stock Coverage

Company
Date
Position
Action
Price Target
No. of Ratings
Success Rate
Avg. Return
CUMB
Virtus Cumberland Municipal Bond ETF
Jun 18, 2012
Hold
Reiterated
1Ratings
0.00%
CADX
Cadence Pharma
Jun 18, 2012
Hold
Reiterated
1Ratings
0.00%
Alkermes
May 24, 2013
Buy
Reiterated
$37.00
(41.82% Upside)
2Ratings
100%
+26.30%
MNTA
Momenta Pharma
Jun 06, 2013
Buy
Upgraded
2Ratings
0%
-1.20%
SLXP
Salix
Jul 10, 2014
Hold
Reiterated
3Ratings
0.00%
HSP
Hospira Inc
Jul 31, 2014
Hold
Reiterated
4Ratings
0.00%
AUXL
Auxilium
Sep 19, 2014
Hold
Downgraded
5Ratings
100%
+23.13%
Horizon Therapeutics
Jun 26, 2015
Buy
Reiterated
1Ratings
0%
-50.30%
SCMP
Sucampo Pharmaceuticals
Feb 09, 2016
Buy
Initiated
1Ratings
100%
+0.80%
Assertio Therapeutics
Oct 03, 2016
Hold
Reiterated
$26.00
(749.67% Upside)
7Ratings
100%
+29.97%
List of latest recommendations made by Ami Fadia. Click to expand and see Ami Fadia's performance on a particular stock
Disclaimer: TipRanks collects analysts’ ratings and price targets by scanning publicly available reports on financial websites and by receiving reports from analysts, firms, or customers. The information and statistics displayed might not be accurate, complete, or up-to-date. The analyst ratings provided are the sole responsibility of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings, or opinions expressed.
Send Us Reports
If you receive reports that you think we are missing, we will thank you with a free Ultimate upgrade!
Learn More >